BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Alteon Suspends Alagebrium Enrollment On Rat Toxicities
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Alteon Suspends Alagebrium Enrollment On Rat Toxicities
Feb. 28, 2005
By
Karen Carey
No Comments
Alteon Inc. voluntarily suspended enrollment in its ongoing Phase II trials of alagebrium after preclinical data indicated high doses of the therapy could be associated with liver cell alterations and tumors. (BioWorld Today)
BioWorld